Compare Stocks: OM, TMCI, TLSI, and ELMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELMD Electromed	$27.69 -0.4%	$32.42	$23.01 ▼ $47.40	$230.38M	0.4	78,847 shs	51,017 shs
OM Outset Medical	$4.05 -1.0%	$3.89	$2.84 ▼ $15.94	$76.88M	1.99	218,619 shs	72,777 shs
TLSI TriSalus Life Sciences	$4.06 -1.7%	$4.88	$2.20 ▼ $7.95	$254.31M	0.47	500,315 shs	198,946 shs
TMCI Treace Medical Concepts	$3.95 +1.8%	$4.53	$1.17 ▼ $7.08	$252.01M	1.48	239,469 shs	161,174 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELMD Electromed	-0.40%	-1.46%	+2.29%	-39.34%	+10.23%
OM Outset Medical	-0.98%	+2.27%	+22.36%	-8.58%	-74.38%
TLSI TriSalus Life Sciences	-1.69%	-6.02%	-14.71%	-1.93%	-16.29%
TMCI Treace Medical Concepts	+1.80%	-10.02%	-12.80%	-8.56%	-35.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELMD Electromed	$27.69 -0.4%	$32.42	$23.01 ▼ $47.40	$230.38M	0.4	78,847 shs	51,017 shs
OM Outset Medical	$4.05 -1.0%	$3.89	$2.84 ▼ $15.94	$76.88M	1.99	218,619 shs	72,777 shs
TLSI TriSalus Life Sciences	$4.06 -1.7%	$4.88	$2.20 ▼ $7.95	$254.31M	0.47	500,315 shs	198,946 shs
TMCI Treace Medical Concepts	$3.95 +1.8%	$4.53	$1.17 ▼ $7.08	$252.01M	1.48	239,469 shs	161,174 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELMD Electromed	-0.40%	-1.46%	+2.29%	-39.34%	+10.23%
OM Outset Medical	-0.98%	+2.27%	+22.36%	-8.58%	-74.38%
TLSI TriSalus Life Sciences	-1.69%	-6.02%	-14.71%	-1.93%	-16.29%
TMCI Treace Medical Concepts	+1.80%	-10.02%	-12.80%	-8.56%	-35.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELMD Electromed	2.75	Moderate Buy	$43.75	58.00% Upside
OM Outset Medical	2.40	Hold	$10.00	146.91% Upside
TLSI TriSalus Life Sciences	2.40	Hold	$10.20	151.23% Upside
TMCI Treace Medical Concepts	1.86	Reduce	$5.17	30.89% Upside

Current Analyst Ratings Breakdown

Latest OM, TMCI, TLSI, and ELMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	TLSI TriSalus Life Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
9/23/2026	TLSI TriSalus Life Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
9/23/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $12.00
9/10/2026	TLSI TriSalus Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/9/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/9/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/31/2026	TMCI Treace Medical Concepts	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	ELMD Electromed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$50.00
8/26/2026	ELMD Electromed	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $47.00
8/21/2026	OM Outset Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	TMCI Treace Medical Concepts	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELMD Electromed	$73.78M	3.11	$0.67 per share	41.36	$5.10 per share	5.43
OM Outset Medical	$119.48M	0.64	N/A	N/A	$6.99 per share	0.58
TLSI TriSalus Life Sciences	$45.08M	5.55	N/A	N/A	($0.68) per share	-5.97
TMCI Treace Medical Concepts	$212.69M	1.21	N/A	N/A	$1.37 per share	2.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELMD Electromed	$5.15M	$1.31	36.92	N/A	N/A	11.34%	15.71%	13.37%	N/A
OM Outset Medical	-$81.65M	-$4.09	N/A	N/A	N/A	-63.06%	-61.67%	-28.25%	11/9/2026 (Estimated)
TLSI TriSalus Life Sciences	-$39.23M	-$1.30	N/A	N/A	N/A	-62.59%	N/A	-64.47%	11/12/2026 (Estimated)
TMCI Treace Medical Concepts	-$59M	-$0.93	N/A	N/A	N/A	-28.99%	-71.37%	-30.49%	11/5/2026 (Estimated)

Latest OM, TMCI, TLSI, and ELMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	TMCI Treace Medical Concepts	-$0.26	N/A	N/A	N/A	$47.71 million	N/A
8/7/2026	Q2 2026	TMCI Treace Medical Concepts	-$0.2980	-$0.24	+$0.0580	-$0.24	$44.02 million	$45.38 million
8/6/2026	Q2 2026	OM Outset Medical	-$0.7167	-$0.80	-$0.0833	-$0.97	$28.97 million	$31.64 million
8/6/2026	Q2 2026	TLSI TriSalus Life Sciences	-$0.1550	-$0.16	-$0.0050	-$0.16	$10.27 million	$11.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELMD Electromed	N/A	N/A	N/A	N/A	N/A
OM Outset Medical	N/A	N/A	N/A	N/A	N/A
TLSI TriSalus Life Sciences	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELMD Electromed	N/A	5.10	4.74
OM Outset Medical	1.03	5.19	4.11
TLSI TriSalus Life Sciences	5.05	5.35	4.97
TMCI Treace Medical Concepts	0.83	2.90	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELMD Electromed	40.82%
OM Outset Medical	N/A
TLSI TriSalus Life Sciences	2.58%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
ELMD Electromed	11.00%
OM Outset Medical	2.50%
TLSI TriSalus Life Sciences	16.30%
TMCI Treace Medical Concepts	23.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELMD Electromed	197	8.29 million	7.36 million	Optionable
OM Outset Medical	310	18.80 million	18.33 million	Not Optionable
TLSI TriSalus Life Sciences	102	61.58 million	51.54 million	Not Optionable
TMCI Treace Medical Concepts	450	65.04 million	49.80 million	Optionable

OM, TMCI, TLSI, and ELMD Headlines

Recent News About These Companies

Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Up 5.03%

October 10 at 1:21 AM | aaii.comA

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Consensus Target Price of $5.17 According to Analysts

September 30, 2026 | americanbankingnews.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Consensus Target Price of $5.17 According to Brokerages

September 30, 2026 | marketbeat.com

Bank of America Corp DE Acquires 3,305,100 Shares of Treace Medical Concepts, Inc. $TMCI

September 26, 2026 | marketbeat.com

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 25, 2026 | prnewswire.com

Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?

September 22, 2026 | insidermonkey.com

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D(R) Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty(R) Procedure

September 18, 2026 | marketscreener.comM

Treace Medical Concepts, Inc.: Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D Study Demonstrating Sustained, Positive Outcomes of the ...

September 18, 2026 | finanznachrichten.de

Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting

September 17, 2026 | quiverquant.comQ

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

September 17, 2026 | globenewswire.com

Treace Highlights Foot & Ankle Portfolio Updates At 2026 AOFAS Annual Meeting

September 16, 2026 | rttnews.com

Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026

September 15, 2026 | quiverquant.comQ

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

September 15, 2026 | globenewswire.com

Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 5,000 Shares

August 25, 2026 | insidertrades.com

Treace Medical Concepts Earnings Call Signals Cautious Rebound

August 18, 2026 | tipranks.com

Treace Medical (TMCI) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary

August 8, 2026 | finance.yahoo.com

Treace Medical Concepts: Q2 Earnings Snapshot

August 7, 2026 | seattlepi.comS

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2026 | zacks.com

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

August 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OM, TMCI, TLSI, and ELMD Company Descriptions

Electromed NYSE:ELMD

$27.69 -0.11 (-0.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$27.41 -0.28 (-1.03%)

As of 10/9/2026 08:00 PM Eastern

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Outset Medical NASDAQ:OM

$4.05 -0.04 (-0.98%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.05 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

TriSalus Life Sciences NASDAQ:TLSI

$4.06 -0.07 (-1.69%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.02 (+0.59%)

As of 10/9/2026 07:47 PM Eastern

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Treace Medical Concepts NASDAQ:TMCI

$3.95 +0.07 (+1.80%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.94 -0.01 (-0.13%)

As of 10/9/2026 07:30 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OM, TMCI, TLSI, and ELMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OM, TMCI, TLSI, and ELMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OM, TMCI, TLSI, and ELMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OM, TMCI, TLSI, and ELMD Company Descriptions

Electromed NYSE:ELMD

Outset Medical NASDAQ:OM

TriSalus Life Sciences NASDAQ:TLSI

Treace Medical Concepts NASDAQ:TMCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OM, TMCI, TLSI, and ELMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OM, TMCI, TLSI, and ELMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OM, TMCI, TLSI, and ELMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OM, TMCI, TLSI, and ELMD Company Descriptions

Electromed NYSE:ELMD

Outset Medical NASDAQ:OM

TriSalus Life Sciences NASDAQ:TLSI

Treace Medical Concepts NASDAQ:TMCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools